Hansa Biopharma AB - Company Profile
Powered by
All the data and insights you need on Hansa Biopharma AB in one report.
- Save hours of research time and resources with
our up-to-date Hansa Biopharma AB Strategy Report
- Understand Hansa Biopharma AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Hansa Biopharma AB (Hansa Biopharma) focuses on the development of novel immunomodulatory enzymes for transplantation, gene therapy, cancer and acute autoimmune diseases. The company's lead project, imlifidase is a proprietary antibody cleaving enzyme for kidney transplant patients which is protected by 6 patent families. Its preclinical assets include NiceR for recurring treatment in autoimmune disease, transplantation, and cancer; and EnzE, cancer immunotherapy. Hansa Biopharma offers a novel diagnostic method HBP-assay (serum quantification of Heparin Binding Protein) to help predict severe sepsis in patients with infectious disease symptoms. The company has out-licensed its HBP-assay (serum quantification of Heparin-Binding Protein), a novel diagnostic method to help predict severe sepsis in patients with infectious disease symptoms to Axis-Shield Diagnostics. It has its operations in Other European Countries and the US. Hansa Biopharma is headquartered in Lund, Sweden.
Hansa Biopharma AB premium industry data and analytics
Products and Services
Products |
---|
Pipeline Drugs:- |
Imlifidase: |
Kidney Transplantation |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In April, the company announced collaboration agreement with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. |
2022 | Contracts/Agreements | In January, the company entered into an agreement with AskBio to evaluate the potential use of imlifidase as a pre-treatment prior to the administration of gene therapy in Pompe disease . |
2021 | Contracts/Agreements | In March, the company entered into a research collaboration with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. |
Competitor Comparison
Key Parameters | Hansa Biopharma AB | Swedish Orphan Biovitrum AB | Calliditas Therapeutics AB | BioInvent International AB | Diamyd Medical AB |
---|---|---|---|---|---|
Headquarters | Sweden | Sweden | Sweden | Sweden | Sweden |
City | Lund | Solna | Stockholm | Lund | Stockholm |
State/Province | - | - | Stockholm | - | - |
No. of Employees | 166 | 1,752 | 195 | 111 | 26 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Peter Nicklin | Chairman | Executive Board | 2022 | 60 |
Soren Tulstrup | President; Chief Executive Officer | Senior Management | 2018 | 58 |
Evan Ballantyne | Chief Financial Officer | Senior Management | 2024 | - |
Achim Kaufhold | Chief Medical Officer; Senior Vice President | Senior Management | 2020 | 66 |
Hitto Kaufmann Ph.D | Chief Scientific Officer | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer